Drug
Anti-PD-L1 Antibody-drug Conjugate HLX43 clinical trials
Also written HLX43.
- studies test it
- 15
- open now
- 15
- in phase 3
- 1
- first study started
- 2025
Keep track of what changes. Save the Anti-PD-L1 Antibody-drug Conjugate HLX43 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2025 (10)
| Year | Studies |
|---|---|
| 2025 | 10 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 15
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Anti-PD-L1 Antibody-drug Conjugate HLX43 is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Shanghai Henlius BiotechNCT06907615Written as HLX43 DOSE 1 (2.0 mg/kg)
- A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingPhase 2Shanghai Henlius BiotechNCT07253142Written as HLX43 dose 1
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingPhase 2Shanghai Henlius BiotechNCT07269782Written as HLX43 DOSE 1
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07459751Written as HLX43
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06769113Written as HLX43
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsRecruitingPhase 2Shanghai Henlius BiotechNCT06769152Written as HLX43
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingPhase 2Shanghai Henlius BiotechNCT07487519Written as HLX43 DOSE 1 IN ≥2L TNBC
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07459738Written as HLX43
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT06857279Written as HLX43 DOSE 1
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07301229Written as HLX43 DOSE 1 (2.5 mg/kg)
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06839066Written as HLX43 DOSE 1
- Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT07115485Written as HLX43 DOSE 1
- A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Shanghai Henlius BiotechNCT06848699Written as HLX43 dose 1
- Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerRecruitingPhase 2Shanghai Henlius BiotechNCT07106892Written as HLX43 Dose 1;
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06742892Written as HLX43 DOSE 1